An observational study in Long-term and Permanent Contraceptive Methods, sponsored by FHI 360. Completed at 1 site in Madagascar. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-03-29.
Sponsored by FHI 360 · Observational
This one-year observational study will monitor the contraceptive effectiveness, safety and acceptability of Zarin during the first year of use after the method has been approved for public use in Madagascar. It will be implemented by Marie Stopes Madagascar with technical support from Marie Stopes International and FHI. 300 women of reproductive age who selected Zarin as their primary method of contraception will be enrolled in the study at the MSM outreach sites and static clinics.
This one-year observational study will monitor the contraceptive effectiveness, safety and acceptability of Zarin during the first year of use after the method has been approved for public use in Madagascar. It will be implemented by Marie Stopes Madagascar with technical support from Marie Stopes International and FHI. 300 women of reproductive age who selected Zarin as their primary method of contraception will be enrolled in the study at the MSM outreach sites and static clinics.
FHI 360 is the lead sponsor of 59 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
healthy women of any age
Exclusion Criteria:
-
healthy volunteers
The cumulative probability of pregnancy through one year
Time frame: 1 year
Prevalence and incidence rate of adverse events
Time frame: 1 year
Prevalence and incidence rates of immediate and delayed complications associated with insertion or removal
Time frame: 1 year
The cumulative probability of early discontinuation through one year
Time frame: 1 year
Reasons for discontinuation
Time frame: 1 year
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
FHI 360